Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. reports developments across a diversified life sciences, diagnostics, genomics and consumer health portfolio. Recurring company updates include the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity tied to legacy COVID-19 testing receivables, and Nebula Genomics, including the DNA Complete direct-to-consumer whole genome sequencing platform.
PRPH news also covers capital-structure actions, convertible debt conversions, financing discussions, operating and financial results, governance matters, and the company’s trading-status transition from Nasdaq and the Pink Sheets to the OTC market. These updates frame ProPhase as an OTC-traded healthcare issuer with diagnostic, genomic data, consumer health, and receivables-related assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
COMSovereign Holding Corp. (NASDAQ: COMS, COMSP) announced the appointment of Bill White as an independent director and Chair of the Audit Committee, effective April 27, 2023. White brings over 30 years of experience in financial management and operations, previously serving as CFO for ProPhase Labs and Intellicheck, among others. His extensive background includes expertise in managing growth, strategic planning, and cost management. CEO David Knight emphasized White's alignment with the company's growth plans and the importance of enhancing finance operations. COMSovereign is focusing on its core wireless connectivity offerings, aiming to leverage its unique technology and intellectual property for revenue growth.
Summary not available.
ProPhase Labs, Inc. (NASDAQ: PRPH) will present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 10:30 am PST (1:30 pm EST). CEO Ted Karkus will lead the presentation and answer questions afterward. Interested parties can access the live event via the provided webcast link.
For those attending, 1x1 investor meetings can be scheduled at the conference venue in Las Vegas. ProPhase Labs specializes in diagnostics, genomics, and biotech, leveraging CLIA lab services for whole genome sequencing and traditional molecular lab services, including COVID-19 testing. The company operates several subsidiaries focused on diverse health and biotechnology solutions.
ProPhase Labs (NASDAQ: PRPH) reported a significant financial turnaround for the year ending December 31, 2022, achieving net revenues of $122.6 million, up 55% from $79.0 million in 2021. The company also posted a net income of $18.5 million ($1.17/share) compared to $6.3 million ($0.41/share) the previous year. Adjusted EBITDA rose to $38.6 million. A $5.9 million charge related to bad debts was noted, stemming from halted HRSA reimbursements for uninsured patients. ProPhase acquired the rights to develop several promising therapeutics and is focusing on global expansion opportunities with the BE-Smart cancer test. A conference call is scheduled for March 28, 2023, to discuss results and future plans.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on March 28, 2023, at 11:00 a.m. Eastern to discuss its 2022 financial results. CEO Ted Karkus will host the call, which will include a Q&A session.
Participants can register for the call via a provided link, and dial-in options are available for those without internet access. A replay will be available shortly after the call.
ProPhase specializes in diagnostics, genomics, and biotech, leveraging CLIA lab services for genome sequencing, and operates a contract manufacturing subsidiary, Pharmaloz.
ProPhase Labs, Inc. (NASDAQ: PRPH) has announced a new stock repurchase program of up to $6 million. This decision follows the expiration of the previous buyback program in February 2023. Over the last six months, ProPhase has retired 1.2 million shares. The new buyback will occur over the next six months and will depend on various factors, including market conditions. CEO Ted Karkus emphasized the company's strong execution over the past two years, highlighting growth in subsidiaries such as Pharmaloz and Nebula Genomics with expected revenue increases. The development of the BE-Smart Esophageal Cancer Test is also progressing well, with a potential launch later this year.